BioLife Solutions (BLFS)
Market Price (5/2/2026): $21.195 | Market Cap: $1.0 BilSector: Health Care | Industry: Health Care Supplies
BioLife Solutions (BLFS)
Market Price (5/2/2026): $21.195Market Cap: $1.0 BilSector: Health CareIndustry: Health Care Supplies
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 21% Low stock price volatilityVol 12M is 46% Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, Biopharmaceutical R&D, Show more. | Weak multi-year price returns2Y Excs Rtn is -21%, 3Y Excs Rtn is -60% Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 10.49 | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -17 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -17% Expensive valuation multiplesP/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 51x Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 24% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -4.5% Key risksBLFS key risks include [1] high customer concentration, Show more. |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 21% |
| Low stock price volatilityVol 12M is 46% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, Biopharmaceutical R&D, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -21%, 3Y Excs Rtn is -60% |
| Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 10.49 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -17 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -17% |
| Expensive valuation multiplesP/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 51x |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 24% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -4.5% |
| Key risksBLFS key risks include [1] high customer concentration, Show more. |
Qualitative Assessment
AI Analysis | Feedback
1. Macroeconomic headwinds and broader healthcare sector weakness contributed to downward pressure. BioLife Solutions' stock experienced a nearly 5% decline on at least one occasion due to broader market pressures, including geopolitical uncertainty from U.S.-Iran tensions and surging oil prices, which particularly affected small-cap healthcare stocks. Furthermore, the stock underperformed the broader US Life Sciences industry and the overall US market during the specified period.
2. Anticipation and potential caution surrounding upcoming Q1 2026 earnings may have influenced investor sentiment. While BioLife Solutions is scheduled to report its Q1 2026 financial results on May 7, 2026, with analysts projecting earnings of $0.01 per share and revenue of $25.664 million, the announcement of this earnings date on April 23, 2026, was followed by a 1.57% decline in the stock, suggesting some investor caution or profit-taking in the lead-up to the report.
Show more
Stock Movement Drivers
Fundamental Drivers
The -2.7% change in BLFS stock from 1/31/2026 to 5/1/2026 was primarily driven by a -6.0% change in the company's P/S Multiple.| (LTM values as of) | 1312026 | 5012026 | Change |
|---|---|---|---|
| Stock Price ($) | 21.80 | 21.21 | -2.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 93 | 96 | 4.0% |
| P/S Multiple | 11.3 | 10.6 | -6.0% |
| Shares Outstanding (Mil) | 48 | 48 | -0.5% |
| Cumulative Contribution | -2.7% |
Market Drivers
1/31/2026 to 5/1/2026| Return | Correlation | |
|---|---|---|
| BLFS | -2.7% | |
| Market (SPY) | 3.6% | 44.7% |
| Sector (XLV) | -5.8% | 54.6% |
Fundamental Drivers
The -23.9% change in BLFS stock from 10/31/2025 to 5/1/2026 was primarily driven by a -31.6% change in the company's P/S Multiple.| (LTM values as of) | 10312025 | 5012026 | Change |
|---|---|---|---|
| Stock Price ($) | 27.87 | 21.21 | -23.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 86 | 96 | 12.1% |
| P/S Multiple | 15.5 | 10.6 | -31.6% |
| Shares Outstanding (Mil) | 48 | 48 | -0.7% |
| Cumulative Contribution | -23.9% |
Market Drivers
10/31/2025 to 5/1/2026| Return | Correlation | |
|---|---|---|
| BLFS | -23.9% | |
| Market (SPY) | 5.5% | 41.0% |
| Sector (XLV) | 1.5% | 47.9% |
Fundamental Drivers
The -12.0% change in BLFS stock from 4/30/2025 to 5/1/2026 was primarily driven by a -29.6% change in the company's P/S Multiple.| (LTM values as of) | 4302025 | 5012026 | Change |
|---|---|---|---|
| Stock Price ($) | 24.11 | 21.21 | -12.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 75 | 96 | 28.9% |
| P/S Multiple | 15.1 | 10.6 | -29.6% |
| Shares Outstanding (Mil) | 47 | 48 | -3.1% |
| Cumulative Contribution | -12.0% |
Market Drivers
4/30/2025 to 5/1/2026| Return | Correlation | |
|---|---|---|
| BLFS | -12.0% | |
| Market (SPY) | 30.4% | 44.5% |
| Sector (XLV) | 5.2% | 46.8% |
Fundamental Drivers
The 20.8% change in BLFS stock from 4/30/2023 to 5/1/2026 was primarily driven by a 26.2% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 4302023 | 5012026 | Change |
|---|---|---|---|
| Stock Price ($) | 17.56 | 21.21 | 20.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 76 | 96 | 26.2% |
| P/S Multiple | 9.9 | 10.6 | 7.7% |
| Shares Outstanding (Mil) | 43 | 48 | -11.1% |
| Cumulative Contribution | 20.8% |
Market Drivers
4/30/2023 to 5/1/2026| Return | Correlation | |
|---|---|---|
| BLFS | 20.8% | |
| Market (SPY) | 78.7% | 41.6% |
| Sector (XLV) | 14.3% | 36.9% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| BLFS Return | -7% | -51% | -11% | 60% | -7% | -13% | -47% |
| Peers Return | 44% | -37% | 1% | -19% | 3% | -17% | -37% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 5% | 92% |
Monthly Win Rates [3] | |||||||
| BLFS Win Rate | 42% | 42% | 42% | 50% | 42% | 50% | |
| Peers Win Rate | 65% | 35% | 48% | 43% | 50% | 20% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| BLFS Max Drawdown | -26% | -72% | -51% | -7% | -20% | -25% | |
| Peers Max Drawdown | -5% | -48% | -32% | -29% | -33% | -27% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -7% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: CYRX, AZTA, TMO, DHR, RGEN.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 5/1/2026 (YTD)
How Low Can It Go
| Event | BLFS | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -26.1% | -18.8% |
| % Gain to Breakeven | 35.3% | 23.1% |
| Time to Breakeven | 190 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -53.7% | -9.5% |
| % Gain to Breakeven | 115.9% | 10.5% |
| Time to Breakeven | 193 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -24.8% | -6.7% |
| % Gain to Breakeven | 33.0% | 7.1% |
| Time to Breakeven | 28 days | 31 days |
| 2020 COVID-19 Crash | ||
| % Loss | -48.8% | -33.7% |
| % Gain to Breakeven | 95.2% | 50.9% |
| Time to Breakeven | 64 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -31.6% | -19.2% |
| % Gain to Breakeven | 46.2% | 23.7% |
| Time to Breakeven | 41 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -20.8% | -3.7% |
| % Gain to Breakeven | 26.2% | 3.9% |
| Time to Breakeven | 63 days | 6 days |
In The Past
BioLife Solutions's stock fell -26.1% during the 2025 US Tariff Shock. Such a loss loss requires a 35.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | BLFS | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -26.1% | -18.8% |
| % Gain to Breakeven | 35.3% | 23.1% |
| Time to Breakeven | 190 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -53.7% | -9.5% |
| % Gain to Breakeven | 115.9% | 10.5% |
| Time to Breakeven | 193 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -24.8% | -6.7% |
| % Gain to Breakeven | 33.0% | 7.1% |
| Time to Breakeven | 28 days | 31 days |
| 2020 COVID-19 Crash | ||
| % Loss | -48.8% | -33.7% |
| % Gain to Breakeven | 95.2% | 50.9% |
| Time to Breakeven | 64 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -31.6% | -19.2% |
| % Gain to Breakeven | 46.2% | 23.7% |
| Time to Breakeven | 41 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -20.8% | -3.7% |
| % Gain to Breakeven | 26.2% | 3.9% |
| Time to Breakeven | 63 days | 6 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -28.0% | -12.2% |
| % Gain to Breakeven | 38.9% | 13.9% |
| Time to Breakeven | 178 days | 62 days |
| 2014-2016 Oil Price Collapse | ||
| % Loss | -36.7% | -6.8% |
| % Gain to Breakeven | 58.0% | 7.3% |
| Time to Breakeven | 63 days | 15 days |
| 2013 Taper Tantrum | ||
| % Loss | -42.7% | -0.2% |
| % Gain to Breakeven | 74.4% | 0.2% |
| Time to Breakeven | 1210 days | 1 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -69.7% | -17.9% |
| % Gain to Breakeven | 230.0% | 21.8% |
| Time to Breakeven | 2 days | 123 days |
| 2010 Eurozone Sovereign Debt Crisis / Flash Crash | ||
| % Loss | -45.0% | -15.4% |
| % Gain to Breakeven | 81.8% | 18.2% |
| Time to Breakeven | 179 days | 125 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -66.7% | -53.4% |
| % Gain to Breakeven | 200.0% | 114.4% |
| Time to Breakeven | 20 days | 1085 days |
In The Past
BioLife Solutions's stock fell -26.1% during the 2025 US Tariff Shock. Such a loss loss requires a 35.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About BioLife Solutions (BLFS)
AI Analysis | Feedback
Here are 1-3 brief analogies to describe BioLife Solutions (BLFS):
- Like a highly specialized Thermo Fisher Scientific for cell and gene therapy biopreservation.
- The FedEx of ultra-sensitive, temperature-controlled biological materials for the cell and gene therapy industry.
AI Analysis | Feedback
Major Products and Services of BioLife Solutions (BLFS):
- Biopreservation Media Products: Proprietary media such as HypoThermosol FRS and CryoStor are formulated to mitigate preservation-induced cell damage and death.
- ThawSTAR Thawing Products: Automated vial and cryobag thawing products that control the heat and timing for biologic materials.
- evo Shipping Containers: Cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals.
- Cryogenic Equipment: Includes liquid nitrogen laboratory freezers, cryogenic equipment, and accessories.
- Biological and Pharmaceutical Storage Services: Provides services for the storage of biological and pharmaceutical materials.
AI Analysis | Feedback
BioLife Solutions (BLFS) primarily sells its bioproduction tools and services to other companies within the cell and gene therapy industry. While specific major customer names are not disclosed in the provided company description, the company's customer base consists of entities involved in the research, development, and commercial manufacturing of biologic-based therapies. These major categories of customers include:
- Pharmaceutical and Biotechnology Companies: Firms engaged in the development and commercial production of cell and gene therapies, requiring specialized biopreservation media, thawing devices, and cryogenic storage solutions.
- Research Institutions and Academic Centers: Universities, hospitals, and other research organizations conducting basic and applied research in the fields of cell biology, gene therapy, and regenerative medicine.
- Contract Development and Manufacturing Organizations (CDMOs): Companies that provide outsourced development and manufacturing services for cell and gene therapy products to pharmaceutical and biotech clients.
AI Analysis | Feedback
nullAI Analysis | Feedback
Roderick de Greef, Chief Executive Officer and Chairman of the Board
Mr. de Greef was appointed CEO and Chairman of the Board in October 2023. He has a long history with BioLife Solutions, having previously served as CFO from 2016 to 2021, COO from 2019 to 2021, and President & COO from November 2021 to January 2023. He also served on the company's board of directors from 2000 to 2013 and rejoined in January 2023. Prior to his operational roles at BioLife Solutions, Mr. de Greef spent over two decades as Chief Financial Officer for several public and private life science and medical technology companies. He has been involved in numerous domestic and international mergers and acquisitions and financing transactions. He has also served on the boards of other public companies, including Endologix, Cambridge Heart, Cardiac Science, and Elephant Talk Communications.
Troy Wichterman, Chief Financial Officer
Mr. Wichterman was promoted to Chief Financial Officer in November 2021. He joined BioLife Solutions in 2015 as a financial analyst and advanced through positions of increasing responsibility, including Vice President of Finance since November 2019. He played an integral role in six acquisitions for the company. Before joining BioLife, Mr. Wichterman held various finance and accounting roles at Ventas, a public healthcare REIT, Heitman, a private equity real estate firm, and PricewaterhouseCoopers (PwC).
Aby J. Mathew, PhD, Executive Vice President and Chief Scientific Officer
Dr. Mathew was part of the founding team of BioLife Solutions and is a co-developer of the company's proprietary biopreservation media solutions, including HypoThermosol® and CryoStor®. He is a co-inventor on multiple issued and pending patents related to methods, devices, and formulations for the preservation of cells, tissues, and organs. Dr. Mathew has been conducting research in low-temperature biopreservation since 1994.
Garrie Richardson, Chief Revenue Officer
Mr. Richardson was appointed Chief Revenue Officer in October 2023. He founded SciSafe in 2010 and served as its CEO until BioLife Solutions acquired SciSafe in 2020. Following the acquisition, he served as the General Manager of BioLife's biostorage business before his promotion to Chief Revenue Officer.
AI Analysis | Feedback
Here are the key risks to the business of BioLife Solutions (BLFS):- Dependence on the Cell and Gene Therapy (CGT) Industry and Regulatory Changes: BioLife Solutions' financial performance is closely tied to the cell and gene therapy (CGT) industry, which, despite its rapid growth, exposes the company to sector-specific risks. Any downturns or significant shifts, such as changes in cell and gene therapy regulations or delays in regulatory approvals (e.g., FDA updates on cell therapy manufacturing), could severely impact the adoption of new therapies and, consequently, the demand for BioLife's products and its revenue and growth prospects. Staying ahead of these regulatory changes is crucial for the company's success.
- Intense Competition: BioLife Solutions operates in a highly competitive market, facing fierce competition from both established and emerging firms, including larger entities with greater financial and human resources. This competitive pressure could lead to price wars, reduced market share, and impact profitability, especially within the biopreservation market. The ongoing challenge of competitors developing more effective or less costly products requires continuous innovation and strategic marketing efforts from BioLife Solutions.
- Customer and Product Concentration: The company faces a risk associated with customer and product concentration. A significant portion of BioLife Solutions' revenue, particularly for its biopreservation media (BPM) products, is generated from a limited number of customers, with the top 20 BPM customers accounting for roughly 80% of BPM revenue. Similarly, a small number of products, such as CryoStor, drive a large share of sales. This reliance makes BioLife Solutions vulnerable to changes or disruptions involving these major clients or specific product sales, which could significantly impact net product revenue and operating results.
AI Analysis | Feedback
nullAI Analysis | Feedback
BioLife Solutions, Inc. provides bioproduction tools and services across several key markets within the cell and gene therapy industry. The addressable markets for its main products and services are significant and are projected to grow considerably.
Biopreservation Media Products (HypoThermosol FRS and CryoStor)
The global biopreservation market for media was valued at USD 1.9 billion in 2025 and is projected to reach USD 15.5 billion by 2035, exhibiting a compound annual growth rate (CAGR) of 23.6% from 2026 to 2035. Another estimate places the global biopreservation market size at USD 4.4 billion in 2024, with a projection to reach USD 7.1 billion by 2029, growing at a CAGR of 9.8%. Focusing specifically on cell cryopreservation, a closely related market, the global market size was valued at US$ 14.9 billion in 2024 and is projected to reach US$ 104.8 billion by 2035, expanding at a CAGR of 19.4% from 2025 to 2035. North America held the largest revenue share in the cell cryopreservation market, at 40.2% in 2024.
ThawSTAR Line (Automated Vial and Cryobag Thawing Products)
The global cryobag thawing system market is expected to grow with a CAGR of 4.1% from 2025 to 2031. The broader global thawing equipment market was valued at USD 180 million in 2021 and is projected to reach USD 321.03 million by 2029, with a CAGR of 7.50% from 2022 to 2029. North America dominates the thawing equipment market due to the prevalence of large blood banks and improved healthcare infrastructure. Another report indicates that the global freeze and thaw systems market size was USD 415.5 million in 2024 and is expected to expand at a CAGR of 7.20% from 2024 to 2031.
Evo Shipping Containers (Cloud-connected Passive Storage and Transport Containers)
These products fall under the cell and gene therapy cold chain logistics market. The global cell and gene therapy third-party logistics market size was estimated at USD 10.71 billion in 2024 and is projected to reach USD 20.04 billion by 2030, growing at a CAGR of 11.05% from 2025 to 2030. North America accounted for the largest market share of 38.13% in this market in 2024. Similarly, the global cell and gene therapy cold chain logistics market size was valued at USD 2.14 billion in 2025 and is anticipated to grow to USD 9.12 billion by 2035, at a CAGR of 15.60% during the forecast period of 2026-2035. Another source estimates the global cell & gene therapy logistics market size at US$ 6.41 billion in 2025, expected to reach around US$ 43.14 billion by 2035, expanding at a CAGR of 21% between 2026 and 2035.
Liquid Nitrogen Laboratory Freezers, Cryogenic Equipment, and Accessories
The global cryogenic equipment market size was valued at USD 22.73 billion in 2024 and is estimated to reach USD 34.40 billion by 2033, exhibiting a CAGR of 4.23% during 2025-2033. Asia Pacific currently dominates this market, holding over 37.8% share in 2024. Other projections for the global cryogenic equipment market size include USD 26,573.8 million in 2025, reaching USD 45,390.9 million by 2033 with a CAGR of 7.0% from 2026 to 2033. A related market, the global biopreservation media storage equipment market, was evaluated at USD 1.30 billion in 2025 and is predicted to reach approximately USD 2.69 billion by 2035, growing at a CAGR of 7.55%.
Biological and Pharmaceutical Storage Services
The global biostorage service market was valued at USD 4.6 billion in 2024 and is expected to reach USD 11.0 billion by 2035, growing at a CAGR of approximately 8.2% between 2025 and 2035. Furthermore, the global cryopreservation services market was estimated to be worth USD 8 billion in 2023 and is expected to increase to USD 34.07 billion by 2030, with a projected CAGR of 23% from 2024 to 2030. The global biological sample temperature-controlled storage services market size was valued at USD 619 million in 2025 and is projected to grow to USD 1,292 million by 2034, exhibiting a CAGR of 11.4%. For pharmaceutical-specific storage, the global pharmaceutical stability and storage services market was valued at USD 15 billion in 2024 and is projected to exhibit a 6.5% CAGR from 2025 to 2034.
AI Analysis | Feedback
BioLife Solutions (NASDAQ: BLFS) is expected to drive future revenue growth over the next 2-3 years through several key factors:
- Growing Adoption of Biopreservation Media in Commercial Cell and Gene Therapies: BioLife Solutions' proprietary biopreservation media products, such as CryoStor and HypoThermosol, are increasingly being adopted by customers with commercially approved cell and gene therapies. This segment represented approximately 40% of total biopreservation media revenue in Q2 2025, with expectations for it to reach 50%-55% in 2026, indicating a significant and recurring revenue stream as more therapies gain approval and patient populations grow. The company's biopreservation media is embedded in 16 approved therapies and utilized in over 250 ongoing commercial clinical trials in the U.S.
- Expansion of the Cell and Gene Therapy (CGT) Market: The broader growth of the cell and gene therapy market is a significant tailwind for BioLife Solutions. This includes the approval of new and unique therapies, geographic expansion of existing treatments, and the application of approved therapies to earlier lines of treatment and additional indications. This expanding market directly increases the demand for BioLife's essential bioproduction tools.
- Multi-Product Penetration and Cross-selling Opportunities: BioLife Solutions is focused on increasing its revenue per patient dose by cross-selling its comprehensive portfolio of cell processing tools beyond just biopreservation media. The strategic divestiture of its evo cold chain logistics business in late 2025 further streamlined the company to focus on its higher-value, recurring cell processing revenue franchises, creating greater opportunities for customers to adopt a wider range of its products, such as ThawSTAR automated thawing devices.
- Strategic Acquisitions and Partnerships: The company's strategy includes expanding its platform through targeted mergers and acquisitions, minority investments, and strategic collaborations. Recent examples include the acquisition of PanTHERA CryoSolutions, an investment in Pluristyx, and a new distribution and development agreement with Qkine Limited for cytokines. These initiatives are designed to broaden BioLife's product offerings and market reach within the cell and gene therapy ecosystem.
- Planned Price Increases: BioLife Solutions anticipates implementing price increases in 2026, with expectations for a 4% to 6% increase depending on the specific product (SKU). This strategy is expected to contribute to revenue growth, with past performance indicating that year-to-date price growth in 2025 was even higher than list price increases due to customer contract negotiations.
AI Analysis | Feedback
Share Repurchases
No information available for share repurchases over the last 3-5 years.Share Issuance
- BioLife Solutions issued 6.65 million shares of common stock as part of the acquisition of Global Cooling, Inc. (Stirling Ultracold) in May 2021.
- As of February 19, 2026, the company had 48.3 million shares issued and outstanding, and 50.2 million shares on a fully diluted basis.
Outbound Investments
- Acquired Global Cooling, Inc. (operating as Stirling Ultracold), a manufacturer of ultra-low temperature mechanical freezers, for approximately $270 million in May 2021, primarily through the issuance of 6.65 million shares of common stock and assumption of $8.7 million in debt.
- Acquired Sexton Biotechnologies, a provider of manufacturing solutions for the cell and gene therapy industry, for a total value of $30 million in August 2021.
- Acquired PanTHERA CryoSolutions, a developer of novel cryopreservation solutions, for $9.3 million in cash and 241,355 shares of BioLife common stock in April 2025, purchasing the 90% of PanTHERA common shares it did not already own.
- Made a $2 million strategic investment in Pluristyx through convertible notes in July 2025, which also included a board observer seat and rights related to potential future acquisitions.
- Divested its evo cold chain logistics subsidiary for $23.5 million in cash in 2025.
- Divested SciSafe for $73 million in cash and CBS for $6.1 million.
Capital Expenditures
- Capital expenditures for the fourth quarter of 2025 were $4.4 million.
- Planned capital projects for Q1 2026 include approximately $5.5 million for a Bothell media cleanroom.
- Planned capital projects for H2 2027 include approximately $15 million for an Indianapolis hPL facility.
Latest Trefis Analyses
Trade Ideas
Select ideas related to BLFS.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 04302026 | GEHC | GE HealthCare Technologies | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | IQV | IQVIA | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | UHS | Universal Health Services | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ABT | Abbott Laboratories | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ZBIO | Zenas BioPharma | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 71.06 |
| Mkt Cap | 3.9 |
| Rev LTM | 667 |
| Op Inc LTM | 12 |
| FCF LTM | 61 |
| FCF 3Y Avg | 63 |
| CFO LTM | 90 |
| CFO 3Y Avg | 97 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 8.2% |
| Rev Chg 3Y Avg | -0.2% |
| Rev Chg Q | 8.4% |
| QoQ Delta Rev Chg LTM | 2.1% |
| Op Inc Chg LTM | 18.8% |
| Op Inc Chg 3Y Avg | -12.2% |
| Op Mgn LTM | 1.4% |
| Op Mgn 3Y Avg | -2.3% |
| QoQ Delta Op Mgn LTM | 1.0% |
| CFO/Rev LTM | 16.7% |
| CFO/Rev 3Y Avg | 14.7% |
| FCF/Rev LTM | 8.8% |
| FCF/Rev 3Y Avg | 9.9% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 3.9 |
| P/S | 4.5 |
| P/Op Inc | 4.2 |
| P/EBIT | 2.0 |
| P/E | 16.6 |
| P/CFO | 20.9 |
| Total Yield | 1.9% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 1.2% |
| D/E | 0.1 |
| Net D/E | -0.0 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 4.5% |
| 3M Rtn | -19.3% |
| 6M Rtn | -18.0% |
| 12M Rtn | -7.7% |
| 3Y Rtn | -21.5% |
| 1M Excs Rtn | -5.5% |
| 3M Excs Rtn | -23.5% |
| 6M Excs Rtn | -22.1% |
| 12M Excs Rtn | -38.3% |
| 3Y Excs Rtn | -95.7% |
Price Behavior
| Market Price | $21.21 | |
| Market Cap ($ Bil) | 1.0 | |
| First Trading Date | 05/26/1992 | |
| Distance from 52W High | -26.3% | |
| 50 Days | 200 Days | |
| DMA Price | $20.44 | $23.77 |
| DMA Trend | down | down |
| Distance from DMA | 3.8% | -10.8% |
| 3M | 1YR | |
| Volatility | 49.6% | 46.6% |
| Downside Capture | 1.00 | 1.22 |
| Upside Capture | 122.71 | 142.85 |
| Correlation (SPY) | 43.1% | 43.7% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.22 | 1.70 | 1.45 | 1.39 | 1.64 | 1.52 |
| Up Beta | 0.92 | 1.42 | 1.10 | 1.55 | 1.65 | 1.39 |
| Down Beta | -2.62 | 2.02 | 2.00 | 0.57 | 1.02 | 1.31 |
| Up Capture | 132% | 118% | 126% | 125% | 181% | 480% |
| Bmk +ve Days | 15 | 22 | 31 | 66 | 141 | 428 |
| Stock +ve Days | 14 | 25 | 36 | 61 | 124 | 372 |
| Down Capture | 342% | 221% | 161% | 170% | 167% | 111% |
| Bmk -ve Days | 4 | 18 | 30 | 56 | 108 | 321 |
| Stock -ve Days | 8 | 18 | 28 | 63 | 125 | 372 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with BLFS | |
|---|---|---|---|---|
| BLFS | -8.3% | 46.4% | -0.05 | - |
| Sector ETF (XLV) | 5.2% | 16.0% | 0.13 | 46.6% |
| Equity (SPY) | 30.6% | 12.5% | 1.88 | 44.2% |
| Gold (GLD) | 39.5% | 27.2% | 1.20 | 5.2% |
| Commodities (DBC) | 51.5% | 17.9% | 2.20 | -9.0% |
| Real Estate (VNQ) | 13.1% | 13.5% | 0.67 | 33.9% |
| Bitcoin (BTCUSD) | -18.2% | 42.1% | -0.36 | 18.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with BLFS | |
|---|---|---|---|---|
| BLFS | -8.2% | 66.6% | 0.15 | - |
| Sector ETF (XLV) | 5.0% | 14.6% | 0.17 | 38.0% |
| Equity (SPY) | 12.8% | 17.1% | 0.59 | 46.8% |
| Gold (GLD) | 20.5% | 17.9% | 0.94 | 6.5% |
| Commodities (DBC) | 14.3% | 19.1% | 0.61 | 4.6% |
| Real Estate (VNQ) | 3.5% | 18.8% | 0.09 | 41.6% |
| Bitcoin (BTCUSD) | 7.4% | 56.1% | 0.35 | 24.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with BLFS | |
|---|---|---|---|---|
| BLFS | 28.1% | 68.0% | 0.66 | - |
| Sector ETF (XLV) | 9.1% | 16.5% | 0.45 | 30.8% |
| Equity (SPY) | 14.9% | 17.9% | 0.71 | 37.5% |
| Gold (GLD) | 13.6% | 15.9% | 0.71 | 4.7% |
| Commodities (DBC) | 9.7% | 17.7% | 0.46 | 6.1% |
| Real Estate (VNQ) | 5.7% | 20.7% | 0.24 | 29.2% |
| Bitcoin (BTCUSD) | 67.4% | 66.9% | 1.07 | 15.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 2/26/2026 | 7.7% | -10.5% | -17.3% |
| 11/6/2025 | -4.0% | -7.0% | -8.4% |
| 8/7/2025 | 9.9% | 22.7% | 27.0% |
| 5/8/2025 | 4.2% | -1.7% | 6.6% |
| 11/12/2024 | -9.0% | -15.3% | 0.8% |
| 8/8/2024 | 11.0% | 13.3% | 1.7% |
| 5/9/2024 | 8.5% | 22.0% | 19.5% |
| 8/8/2023 | -28.7% | -33.3% | -29.3% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 13 | 11 | 12 |
| # Negative | 6 | 8 | 7 |
| Median Positive | 7.8% | 13.3% | 14.5% |
| Median Negative | -7.4% | -9.4% | -17.3% |
| Max Positive | 42.8% | 31.1% | 32.7% |
| Max Negative | -29.5% | -33.3% | -29.3% |
Recent Forward Guidance [BETA]
Latest: Q4 2025 Earnings Reported 2/26/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | 112.50 Mil | 113.75 Mil | 115.00 Mil | 19.1% | Raised | Guidance: 95.50 Mil for 2025 | |
| 2026 Revenue Growth | 17.0% | 18.5% | 20.0% | ||||
Prior: Q3 2025 Earnings Reported 11/6/2025
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2025 Total Revenue | 95.00 Mil | 95.50 Mil | 96.00 Mil | -5.9% | Lowered | Guidance: 101.50 Mil for 2025 | |
| 2025 Cell Processing platform revenue | 93.00 Mil | 93.50 Mil | 94.00 Mil | 1.6% | Raised | Guidance: 92.00 Mil for 2025 | |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Foster, Karen A | Chief Quality and Operations | Direct | Sell | 3312026 | 19.17 | 2,577 | 49,401 | 2,084,891 | Form |
| 2 | Foster, Karen A | Chief Quality and Operations | Direct | Sell | 3092026 | 20.00 | 500 | 10,000 | 2,264,840 | Form |
| 3 | Foster, Karen A | Chief Quality and Operations | Direct | Sell | 3092026 | 20.15 | 96,923 | 1,952,998 | 2,291,901 | Form |
| 4 | Werner, Sean | Chief Technology Officer | Direct | Sell | 3052026 | 20.74 | 111 | 2,302 | 1,035,590 | Form |
| 5 | Foster, Karen A | Chief Quality and Operations | Direct | Sell | 3052026 | 20.74 | 418 | 8,669 | 4,369,192 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.